Sensus Healthcare price target lowered to $13 from $18 at Lake Street

Lake Street analyst Ben Haynor lowered the firm’s price target on Sensus Healthcare (SRTS) to $13 from $18 and keeps a Buy rating on the shares after having attended the American Academy of Dermatology annual meeting and noting that Sensus’ largest customer, SkinCure Oncology, submitted for 510(k) clearance of GentleBeam, a competitive SRT unit. Sensus management “seemed unphased by the development,” though the firm is reducing its EPS estimates to account for the development, the analyst tells investors.